575 related articles for article (PubMed ID: 31089973)
21. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
[TBL] [Abstract][Full Text] [Related]
23. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB
Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
[TBL] [Abstract][Full Text] [Related]
24. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.
Ju JS; Huang AC; Tung PH; Huang CH; Chiu TH; Wang CC; Ko HW; Chung FT; Hsu PC; Fang YF; Guo YK; Kuo CS; Yang CT
Sci Rep; 2023 Nov; 13(1):20323. PubMed ID: 37989860
[TBL] [Abstract][Full Text] [Related]
25. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
[TBL] [Abstract][Full Text] [Related]
27. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
31. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
32. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
33. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B; Sendur MAN; Yucel S; Celik E; Ozyukseler DT; Ayhan M; Basoglu T; Ilhan A; Akdeniz N; Gulmez A; Dogan I; Aktas BY; Gurbuz M; Koca S; Paydas S; Tatli AM; Cinkir HY; Alan O; Erol C; Hizal M; Kut E; Menevse S; Sakalar T; Taskaynatan H; Deniz GI; Karaagac M; Avci O; Sen E; Karatas F; Akinci MB; Dede DS; Demir A; Demirkazık A; Oksuzoglu B; Kilickap S; Yumuk F; Yalcin B
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2145-2152. PubMed ID: 33433657
[TBL] [Abstract][Full Text] [Related]
34. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
[TBL] [Abstract][Full Text] [Related]
35. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
Lau SC; Chooback N; Ho C; Melosky B
Clin Lung Cancer; 2019 Sep; 20(5):e576-e583. PubMed ID: 31178389
[TBL] [Abstract][Full Text] [Related]
36. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Chang HC; Huang KT; Tseng CC; Chen YM; Lai CH; Chang YP; Chen YC; Chuang HY; Wang CC
Thorac Cancer; 2023 Nov; 14(32):3217-3225. PubMed ID: 37704454
[TBL] [Abstract][Full Text] [Related]
38. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.
Lim J; Samuelsen C; Golembesky A; Shrestha S; Wang L; Griebsch I
Future Oncol; 2019 May; 15(13):1493-1504. PubMed ID: 30888202
[No Abstract] [Full Text] [Related]
39. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
[TBL] [Abstract][Full Text] [Related]
40. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
